Introduction Executive Summary Acquired Hemophilia A: Overview ● Causes ● Mechanism of Action ● Signs and Symptoms ● Diagnosis ● Disease Management Pipeline Therapeutics ● Comparative Analysis Therapeutic Assessment ● Assessment by Product Type ● Assessment by Stage and Product Type ● Assessment by Route of Administration ● Assessment by Stage and Route of Administration ● Assessment by Molecule Type ● Assessment by Stage and Molecule Type Immune Thrombocytopenic Purpura– DelveInsight’s Analytical Perspective In-depth Commercial Assessment ● Immune Thrombocytopenic Purpuracompanies’ collaborations, Licensing, Acquisition -Deal Value Trends Immune Thrombocytopenic PurpuraCollaboration Deals ● Company-Company Collaborations (Licensing / Partnering) Analysis ● Company-University Collaborations (Licensing / Partnering) Analysis Late Stage Products (Phase III) ● Comparative Analysis Rozanolixizumab : UCB ● Product Description ● Research and Development ● Product Development Activities Drug profiles in the detailed report….. Mid Stage Products (Phase II/III) ● Comparative Analysis Batoclimab: HanAll Biopharma ● Product Description ● Research and Development ● Product Development Activities Drug profiles in the detailed report….. Early Stage Products (Phase I) ● Comparative Analysis HMPL-523: Hutchison Medipharma Limited ● Product Description ● Research and Development ● Product Development Activities Drug profiles in the detailed report….. Inactive Products ● Comparative Analysis Immune Thrombocytopenic PurpuraKey Companies Immune Thrombocytopenic PurpuraKey Products Acquired Hemophilia A- Unmet Needs Acquired Hemophilia A- Market Drivers and Barriers Acquired Hemophilia A- Future Perspectives and Conclusion Immune Thrombocytopenic PurpuraAnalyst Views Immune Thrombocytopenic PurpuraKey Companies Appendix

Table 1 Total Products for Acquired Hemophilia A Table 2 Late Stage Products Table 3 Mid Stage Products Table 4 Early Stage Products Table 5 Pre-clinical & Discovery Stage Products Table 6 Assessment by Product Type Table 7 Assessment by Stage and Product Type Table 8 Assessment by Route of Administration Table 9 Assessment by Stage and Route of Administration Table 10 Assessment by Molecule Type Table 11 Assessment by Stage and Molecule Type Table 12 Inactive Products

• UCB • Principia Biopharma • Argenx • HanAll Biopharma • Momenta Pharmaceuticals • Genosco • Takeda • Bioverativ • Hutchison Medipharma Limited